BiotechTube
VITA 34

VITA 34

V3V.DE
Leipzig, Germany· Est.
vita34.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

V3V.DE · Stock Price

EUR 4.15+0.17 (+4.27%)
Market Cap: $86.0M

Historical price data

Overview

VITA 34 AG's mission is to provide biological insurance for families through the cryopreservation of newborn stem cells from umbilical cord blood and tissue. The company has achieved a leading market position in Europe, with over one million samples stored, a GMP-certified facility, and recognition as the 'Top StemCell Bank in Europe 2025'. Its core strategy revolves around scaling its service platform, emphasizing its unique family compatibility screening, and leveraging its large biobank to support both current transplant medicine and future regenerative therapies.

HematologyImmunologyMetabolic DisordersOrthopedicsNeurologyAutoimmune Diseases

Technology Platform

Vertically integrated GMP-certified service platform for the collection, processing, cryopreservation, and long-term storage of hematopoietic and mesenchymal stem cells from umbilical cord blood and tissue, featuring unique pre-screening for family compatibility (Familienoption).

Opportunities

The expansion of regenerative medicine research, particularly using mesenchymal stem cells from cord tissue for conditions like joint disease and neurological disorders, presents a major long-term growth driver.
Furthermore, the company's vast biobank of over one million characterized samples is a strategic asset that could be leveraged for research partnerships and data monetization.

Risk Factors

Key risks include the low statistical probability of autologous use, which challenges the core value proposition; regulatory changes in tissue handling and data privacy; and intense competition from other private banks and public donation programs.
A catastrophic operational failure at its storage facility would pose an existential reputational threat.

Competitive Landscape

VITA 34 competes on scale (largest in Europe), quality (GMP certification), and its unique Familienoption service for family compatibility screening. It faces competition from other national and pan-European private cord blood banks and must continually differentiate itself from the alternative of free public cord blood donation.

More companies in Regenerative Medicine →More companies in Germany →